CG
ABBV icon

Corundum Group’s AbbVie ABBV Stock Holding History

Corundum Group’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.75M Sell
8,055
-256
-3% -$56.8K 0.59% 37
2025
Q4 		$1.9M Buy
8,311
+813
+11% +$185K 0.64% 31
2025
Q3 		$1.74M Sell
7,498
-22
-0.3% -$4.48K 0.71% 32
2025
Q2 		$1.4M Buy
7,520
+2,391
+47% +$444K 0.62% 34
2025
Q1 		$1.07M Sell
5,129
-4,052
-44% -$788K 0.52% 47
2024
Q4 		$1.63M Buy
9,181
+4,159
+83% +$765K 0.61% 48
2024
Q3 		$992K Sell
5,022
-4,211
-46% -$786K 0.45% 52
2024
Q2 		$1.58M Buy
9,233
+4,367
+90% +$723K 0.62% 45
2024
Q1 		$886K Sell
4,866
-102
-2% -$17.6K 0.43% 54
2023
Q4 		$770K Buy
4,968
+106
+2% +$15.5K 0.39% 54
2023
Q3 		$725K Sell
4,862
-873
-15% -$128K 0.41% 56
2023
Q2 		$773K Sell
5,735
-4,295
-43% -$630K 0.39% 61
2023
Q1 		$1.6M Buy
10,030
+3,526
+54% +$539K 0.76% 37
2022
Q4 		$1.05M Buy
6,504
+120
+2% +$18.4K 0.59% 43
2022
Q3 		$857K Buy
6,384
+898
+16% +$129K 0.54% 45
2022
Q2 		$840K Buy
5,486
+100
+2% +$15.3K 0.57% 45
2022
Q1 		$873K Buy
5,386
+143
+3% +$20.8K 0.81% 45
2021
Q4 		$710K Buy
5,243
+547
+12% +$64.6K 0.46% 42
2021
Q3 		$507K Buy
4,696
+488
+12% +$55.8K 0.38% 41
2021
Q2 		$474K Buy
4,208
+57
+1% +$6.42K 0.31% 45
2021
Q1 		$449K Buy
4,151
+87
+2% +$9.31K 0.35% 44
2020
Q4 		$435K Buy
4,064
+325
+9% +$31.2K 0.36% 41
2020
Q3 		$327K Buy
3,739
+231
+7% +$21.7K 0.32% 44
2020
Q2 		$344K Buy
+3,508
New +$309K 0.41% 30

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Corundum Group's ABBV Position: Q1 2026 in Review

Corundum Group reduced its AbbVie (ABBV) stake by 3.1% in Q1 2026, selling an estimated $56.8K and leaving 8,055 shares worth $1.75M. The position accounts for 0.59% of the portfolio, ranked #37.

Corundum Group first reported a position in ABBV in Q2 2020 and has held it in 24 quarters since. The position peaked at $1.9M in Q4 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Corundum Group held 8,055 shares of AbbVie worth $1.75M as of Q1 2026.
  • Corundum Group sold 256 AbbVie shares in Q1 2026, an estimated $56.8K.
  • AbbVie made up 0.59% of Corundum Group's portfolio in Q1 2026, its #37 holding.
  • Corundum Group first reported a position in AbbVie in Q2 2020 and has held it in 24 quarters since.
  • Corundum Group's AbbVie position peaked at $1.9M in Q4 2025.
  • 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Corundum Group's 13F filing for Q1 2026, filed 20 Apr 2026.